Teva Pharmaceutical Industries (NYSE:TEVA) Stock Rated Buy in New Coverage at HC Wainwright

HC Wainwright started coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a research note issued to investors on Monday, Marketbeat reports. The brokerage issued a buy rating and a $52.00 price objective on the stock.

A number of other equities research analysts also recently weighed in on the company. Barclays lifted their target price on Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the stock an “overweight” rating in a report on Thursday, October 15th. Piper Sandler upped their price target on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a research note on Tuesday, July 28th. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Oppenheimer raised their price target on shares of Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the stock an “outperform” rating in a research report on Friday, October 9th. Finally, UBS Group lifted their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a research note on Friday, September 4th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $46.69.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA opened at $41.83 on Monday. The stock has a 50 day moving average price of $39.32 and a 200 day moving average price of $34.68. Teva Pharmaceutical Industries has a 52 week low of $22.70 and a 52 week high of $43.34. The company has a debt-to-equity ratio of 1.56, a quick ratio of 0.67 and a current ratio of 0.88. The stock has a market capitalization of $48.74 billion, a PE ratio of 97.27, a price-to-earnings-growth ratio of 3.89 and a beta of 0.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.14. Teva Pharmaceutical Industries had a net margin of 2.94% and a return on equity of 33.22%. The company had revenue of $4.39 billion during the quarter, compared to the consensus estimate of $4.23 billion. During the same quarter last year, the firm posted $0.78 EPS. The company’s quarterly revenue was down 1.9% on a year-over-year basis. Analysts predict that Teva Pharmaceutical Industries will post 2.00 earnings per share for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 367,600 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $39.06, for a total transaction of $14,358,456.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Brian Savage sold 7,342 shares of the company’s stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $38.85, for a total transaction of $285,236.70. Following the transaction, the insider owned 8,500 shares of the company’s stock, valued at approximately $330,225. This represents a 46.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.54% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Harel Insurance Investments & Financial Services Ltd. increased its position in Teva Pharmaceutical Industries by 2.2% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 45,956,714 shares of the company’s stock valued at $1,384,216,000 after acquiring an additional 1,004,941 shares during the period. WCM Investment Management LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 191.4% during the first quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock worth $1,157,264,000 after purchasing an additional 26,813,522 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Teva Pharmaceutical Industries by 5.8% during the second quarter. Wellington Management Group LLP now owns 7,671,157 shares of the company’s stock worth $259,899,000 after purchasing an additional 419,329 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Teva Pharmaceutical Industries by 1.5% during the first quarter. Janus Henderson Group PLC now owns 4,816,657 shares of the company’s stock worth $145,076,000 after purchasing an additional 72,880 shares during the period. Finally, Bessemer Group Inc. grew its stake in shares of Teva Pharmaceutical Industries by 1.6% in the first quarter. Bessemer Group Inc. now owns 4,350,483 shares of the company’s stock worth $131,036,000 after purchasing an additional 70,058 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

More Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Earnings and guidance beat expectations: Third-quarter adjusted earnings were $0.86 per share versus $0.72 expected, and revenue of about $4.39 billion topped the $4.23 billion consensus. Teva raised its 2026 revenue and product-sales outlook, citing growth in branded medicines. Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up
• Positive Sentiment: UZEDY sales surged: The long-acting schizophrenia treatment generated $85 million in U.S. third-quarter sales, up 96% year over year. Teva lifted its 2026 UZEDY revenue forecast to $290 million–$310 million from $270 million–$290 million. UZEDY Q3 U.S. Net Sales Reach $85M
• Positive Sentiment: Analyst endorsement: TD Cowen raised its price target from $55 to $57 and maintained a Buy rating, signaling confidence in further potential upside. TD Cowen price-target update
• Positive Sentiment: Biosimilar portfolio expansion: Teva secured U.S. commercialization rights to two Samsung Bioepis immunology biosimilars, broadening its product portfolio and potential future revenue sources. Teva and Samsung Bioepis biosimilar agreement
• Negative Sentiment: Drug-development setback and sales pressure: Teva ended its Phase 2 emrusolmin study after an interim review found insufficient efficacy. Quarterly revenue also declined 1.9% year over year, and the company expects U.S. drug-pricing pressure to affect Austedo. Why Teva Is Dropping a Drug Trial While Raising Its Outlook

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company is one of the world’s largest producers of generic medicines and develops, manufactures and distributes prescription products across a broad range of therapeutic areas.

Teva’s portfolio includes generic medicines, specialty pharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products. Its specialty medicines include treatments for neurological and movement disorders, respiratory conditions, migraine and other chronic diseases.